Want to see CSTL full AI Analyst Report?
CSTL Stock Chart & Stats
$24.68
-$0.41(-1.68%)
At close: 4:00 PM EDT
$24.68
-$0.41(-1.68%)
Day’s Range― - ―
52-Week Range$17.72 - $44.28
Previous CloseN/A
Volume124.06K
Average Volume (3M)337.72K
Market Cap
$978.50M
Enterprise Value$494.86
Total Cash (Recent Filing)$266.81M
Total Debt (Recent Filing)$36.65M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding30,549,507
10 Day Avg. Volume322,460
30 Day Avg. Volume337,724
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)2.39
Price to Sales (P/S)3.28
P/FCF Ratio39.81
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$42.00Price Target Upside70.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.45
Revenue Forecast (FY)$352.38M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue & Volume MomentumConsistent top-line growth and a guidance raise signal persistent adoption of Castle’s tests across clinicians. Durable revenue and 32% core test volume growth support scale economics, fund evidence generation and commercial expansion, and underpin multi-quarter cash generation and reinvestment capacity.
Conservative Balance Sheet & Cash RunwayA light debt load and a sizable cash/investment balance provide a durable financial cushion to fund lab capacity, commercialization and clinical programs without near-term solvency pressure. Positive operating and free cash flow across recent periods improves optionality for strategic investments.
Pipeline & Reimbursement ProgressEarly commercial traction for AdvanceAD‑Tx plus favorable CMS crosswalk recommendation are structural positives: they reduce commercialization risk, support reimbursement discussions, and diversify revenue beyond core dermatology assays, strengthening long‑term market positioning.
Bears Say
Inconsistent GAAP ProfitabilityReversion to GAAP losses in 2025 and TTM highlights uneven operating leverage despite revenue growth. Persistent negative net income can depress returns on equity, constrain discretionary spending over time, and make sustained GAAP profitability dependent on margin recovery and disciplined expense control.
Gross Margin CompressionA multi-point decline in adjusted gross margin driven by mix, accruals and higher costs is a structural headwind for a diagnostics model that relies on high per-test margins. Sustained margin pressure reduces room to fund sales, R&D and lab investments while hindering the path to consistent GAAP profitability.
Reimbursement Uncertainty (DecisionDx‑SCC)Uncertain Medicare coverage for a key test is a durable commercial risk in diagnostics: payer decisions materially affect collectability and adoption. A multi‑quarter delay or unfavorable coverage would impair revenue visibility, slow clinical uptake and complicate sales force prioritization across product lines.
Castle Biosciences News
CSTL FAQ
What was Castle Biosciences’s price range in the past 12 months?
Castle Biosciences lowest stock price was $17.72 and its highest was $44.28 in the past 12 months.
What is Castle Biosciences’s market cap?
Castle Biosciences’s market cap is $978.50M.
When is Castle Biosciences’s upcoming earnings report date?
Castle Biosciences’s upcoming earnings report date is Mar 04, 2027 which is in 205 days.
How were Castle Biosciences’s earnings last quarter?
Castle Biosciences released its earnings results on Jul 30, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.407 by $0.337.
Is Castle Biosciences overvalued?
According to Wall Street analysts Castle Biosciences’s price is currently Undervalued.
Does Castle Biosciences pay dividends?
Castle Biosciences does not currently pay dividends.
What is Castle Biosciences’s EPS estimate?
Castle Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Castle Biosciences have?
Castle Biosciences has 30,549,507 shares outstanding.
What happened to Castle Biosciences’s price movement after its last earnings report?
Castle Biosciences reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.407. Following the earnings report the stock price went up 4.517%.
Which hedge fund is a major shareholder of Castle Biosciences?
Currently, no hedge funds are holding shares in CSTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Castle Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.00 (70.18% Upside)
$42.00 (70.18% Upside)
Blogger Sentiment
Bullish
CSTL Sentiment 75%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 205.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
50.24%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.02%
Trailing 12-Months
Company Description
Castle Biosciences
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
CSTL Company Deck
CSTL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents strong operational momentum: revenue and core test volumes grew materially (20% total revenue growth, 32% core volume growth), TissueCypher delivered robust 63% YoY growth and management raised full‑year guidance. The company is investing to scale commercial reach, evidence generation and lab capacity and reports positive adjusted EBITDA and a healthy cash position. Key challenges include margin compression, higher operating expenses that produced a small GAAP net loss in the quarter, uncertainty around Medicare coverage for SCC, and near‑term sales force tradeoffs affecting melanoma seasonality. On balance the positives (revenue/volume acceleration, guidance raise, evidence/regulatory progress, cash runway and adjusted EBITDA) outweigh the negatives.View all CSTL earnings summariesCSTL Stock 12 Month Forecast
Average Price Target
$42.00
▲(70.18% Upside)
Technical Analysis
Ownership Overview
2.30% Insiders
16.18% Mutual Funds
5.04% Other Institutional Investors
61.83% Public Companies and
Individual Investors